OssDsign surpasses 400 patients in PROPEL spine registry evaluating OssDsign Catalyst®
Uppsala, Sweden, September 9, 2026. OssDsign® AB, a cutting edge technology orthobiologics company, announces today that more than 400 patients have been enrolled in the PROPEL registry, a prospective, multi-center, spine fusion registry evaluating its flagship product OssDsign Catalyst. The registry, that was initiated in March 2022, has previously demonstrated a fusion rate of 88.4% among the first 108 patients at 12 months across a highly complex patient cohort, proving its exceptional performance in spinal fusion surgery.
“Being able to enroll 400 subjects in a real-world patient registry is a major milestone, particularly compared to many other existing data sets related to other biologics and synthetics graft options for spinal fusion. OssDsign’s previously published 88.4% fusion rate for OssDsign Catalyst bone graft which was observed with a large group of patients in the United States who underwent complex spinal fusionsurgeries is very impressive, and these results achieved in a challenging patient population with no exclusion criteria certainly serves to only increasemy confidence in the use of Catalyst for my own cases,” said Peter G. Whang, M.D., F.A.C.S., F.A.A.O.S., a Professor in the Department of Orthopaedics and Rehabilitation at the Yale University School of Medicine.
“The PROPEL Registry continues to demonstrate the clinical performance of OssDsign Catalyst in a cohort of patients representative of typical American spinal patients. The fact that patients with multiple surgical risk factors are not excluded speaks to the high quality of this registry data. OssDsign Catalyst’s published data are compelling and reinforce our belief that we offer a strong nanosyntheticTM alternative to iliac bone graft or other more costly proteins or synthetic products. I’m thrilled to announce our PROPEL Registry achieving this 400 patients milestone,” commented Mark Waugh, President and CEO.”
Previously published results from the PROPEL registry are based on 108 patients and the studied population is considered a highly complex patient cohort. At the 12-month follow-up, all patients showed improvement in each health status category assessed, with no unexpected device-related adverse events and a successful fusion rate of 88.4%, and between 84.7% and 93.4% in high-risk subgroups.
Please visit our website to learn more about the PROPEL registry: www.ossdsign.com/clinical-evidence.
For further information, please contact:
Mark Waugh, CEO
+1 (260) 804-1342
mark.waugh@ossdsign.com
Certified Adviser
The Company's Certified Adviser is DNB Carnegie Investment Bank AB (publ)
About the study
PROPEL is a prospective spinal fusion registry that aims to bridge the gap between the device's performance in a controlled clinical trial and its use in everyday clinical practice over time. To date, over 400 patients are enrolled. 108 patients were included in this analysis across six sites; surgery dates ranged from April 25, 2022, to August 21, 2023. Any patient aged 21 years or older, requiring spinal fusion surgery for which OssDsign Catalyst was being used, was considered appropriate for inclusion if, in the investigator’s opinion, the patient could comply with the registry protocol requirements. The primary endpoint was the fusion (bridging bone) assessment at 12 months ± 60 days post-surgery. Clinical outcomes were assessed as secondary endpoints, with success defined as any improvement from baseline scores for the following: Quality of Life Questionnaires (VAS and ODI/NDI, as applicable, and SF-36) and the maintenance or improvement of neurological function. A safety review was also conducted for all Adverse Events (AEs).
The study is published in the latest issue of theBioMedRes Journaland is accessible here:https://biomedres.us/pdfs/BJSTR.MS.ID.009734.pdf
About OssDsign Catalyst®
OssDsign Catalyst is a nanosyntheticTM bone graft that shows rapid and robust bone formation, even in poorly vascularized environments. OssDsign Catalyst’s patented nanocrystalline structure and incorporated silicate ions, which mimic the body’s natural bone, enable bone formation in the centre of the fusion mass.OssDsign Catalyst is designed to deliver a decreased non-union risk, making it highly applicable for both simple and complex patients.
About OssDsign
OssDsign is a developer and global provider of next generation orthobiologics products. Based on cutting edge material science, the company develops and markets products that support the body's own healing capabilities, giving patients back the life they deserve. The company has a strong presence in the U.S. market. OssDsign's share is traded on Nasdaq First North Growth Market in Stockholm, Sweden.
Tags: